A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC) Meeting Abstract
| Authors: | Sequist, L. V.; Anderson, I. C.; Demars, N.; Felip, E.; Harb, W. A.; Huber, R. M.; Kudla, A. J.; Lee, J. K.; Mathews, S.; McClure, T.; Nieva, J. J.; Perol, M.; Shepherd, F. A.; Spira, A. I.; Czibere, A. G. |
| Abstract Title: | A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC) |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-05-20 |
| Start Page: | 483s |
| Language: | English |
| ACCESSION: | WOS:000404711506256 |
| DOI: | 10.1200/JCO.2016.34.15_suppl.TPS9110 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS9110 -- Source: Wos |
